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INTRODUCTION 
ANATOMY OF THE THYROID GLAND1 
The Thyroid Gland (Glandula Thyreiodea; Thyroid Body) — the 
thyroid gland is a highly vascular organ, situated at the front and sides of 
the neck; it consists of right and left lobes connected across the middle 
line by a narrow portion, the isthmus. Its weight is somewhat variable, 
but is usually about 30 grams. It is slightly heavier in the female, in 
whom it becomes enlarged during menstruation and pregnancy 
The lobes (lobuli gl. thyreoideæ) are conical in shape, the apex of 
each being directed upward and lateralward as far as the junction of the 
middle with the lower third of the thyroid cartilage; the base looks 
downward, and is on a level with the fifth or sixth tracheal ring. Each 
lobe is about 5 cm. long; its greatest width is about 3 cm. and its 
thickness about 2 cm. The lateral or superficial surface is convex, and 
covered by the skin, the superficial and deep fasciæ, the 
Sternocleidomastoideus, the superior belly of the Omohyoideus, the 
Sternohyoideus and Sternothyreoideus, and beneath the last muscle by 
the pretracheal layer of the deep fascia, which forms a capsule for the 
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gland. The deep or medial surface is moulded over the underlying 
structures, viz., the thyroid and cricoid cartilages, the trachea, the 
Constrictor pharyngis inferior and posterior part of the 
Cricothyreoideus, the esophagus (particularly on the left side of the 
neck), the superior and inferior thyroid arteries, and the recurrent nerves. 
The anterior border is thin, and inclines obliquely from above downward 
toward the middle line of the neck, while the posterior border is thick 
and overlaps the common carotid artery, and, as a rule, the parathyroids. 
The isthmus (isthmus gl. thyreoidea) connects together the lower 
thirds of the lobes; it measures about 1.25 cm. in breadth, and the same 
in depth, and usually covers the second and third rings of the trachea. Its 
situation and size present, however, many variations. In the middle line 
of the neck it is covered by the skin and fascia, and close to the middle 
line, on either side, by the Sternothyreoideus. Across its upper border 
runs an anastomotic branch uniting the two superior thyroid arteries; at 
its lower border are the inferior thyroid veins. Sometimes the isthmus is 
altogether wanting. 
A third lobe, of conical shape, called the pyramidal lobe, 
frequently arises from the upper part of the isthmus, or from the adjacent 
portion of either lobe, but most commonly the left, and ascends as far as 
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the hyoid bone. It is occasionally quite detached, or may be divided into 
two or more parts. 
A fibrous or muscular band is sometimes found attached, above, 
to the body of the hyoid bone, and below to the isthmus of the gland, or 
its pyramidal lobe. When muscular, it is termed the Levator glandulæ 
thyreoideæ. 
Small detached portions of thyroid tissue are sometimes found in 
the vicinity of the lateral lobes or above the isthmus; they are called 
accessory thyroid glands (glandulæ thyreoideæ accessoriæ). 
 
Scheme showing development of branchial epithelial bodies 
I, II, III, IV. Branchial pouches 
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Development.—The thyroid gland is developed from a median 
diverticulum which appears about the fourth week on the summit of the 
tuberculum impar, but later is found in the furrow immediately behind 
the tuberculum. It grows downward and backward as a tubular duct, 
which bifurcates and subsequently subdivides into a series of cellular 
cords, from which the isthmus and lateral lobes of the thyroid gland are 
developed. The ultimo-branchial bodies from the fifth pharyngeal 
pouches are enveloped by the lateral lobes of the thyroid gland; they 
give rise to the calcitonin-producing cells—also called parafollicular 
cells—of the thyroid gland. The connection of the diverticulum with the 
pharynx is termed the thyroglossal duct; its continuity is subsequently 
interrupted, and it undergoes degeneration, its upper end being 
represented by the foramen cecum of the tongue, and its lower by the 
pyramidal lobe of the thyroid gland 
Structure.—The thyroid gland is invested by a thin capsule of 
connective tissue, which projects into its substance and imperfectly 
divides it into masses of irregular form and size. When the organ is cut 
into, it is of a brownish-red color, and is seen to be made up of a number 
of closed vesicles, containing a yellow glairy fluid, and separated from 
each other by intermediate connective tissue 
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Section of thyroid gland of sheep. X 160. 
The vesicles of the thyroid of the adult animal are generally 
closed spherical sacs; but in some young animals, e. g., young dogs, the 
vesicles are more or less tubular and branched. This appearance is 
supposed to be due to the mode of growth of the gland, and merely 
indicates that an increase in the number of vesicles is taking place. Each 
vesicle is lined by a single layer of cubical epithelium. There does not 
appear to be a basement membrane, so that the epithelial cells are in 
direct contact with the connective-tissue reticulum which supports the 
acini. The vesicles are of various sizes and shapes, and contain as a 
normal product a viscid, homogeneous, semifluid, slightly yellowish, 
colloid material; red corpuscles are found in it in various stages of 
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disintegration and decolorization, the yellow tinge being probably due to 
the hemoglobin, which is thus set free from the colored corpuscles. The 
colloid material contains an iodine compound, iodothyrin, and is readily 
stained by eosin. The thyroid gland prepares and secretes into the 
vascular channels the hormones thyroxine and triiodothyronine, formed 
under normal conditions in the outer pole of the cell and excreted from it 
directly without passing by the indirect route through the follicular 
cavity. In addition to this direct mode of secretion there is an indirect 
mode which consists in the condensation of the secretion into the form 
of droplets, having high content of solids, and the extension of these 
droplets into the follicular cavity. These droplets are formed in the same 
zone of the cell as that in which the primary or direct secretion is 
formed. 
This internal secretion of the thyroid contains the hormones 
thyroxine and triiodothyronine which act as a chemical stimulus to other 
tissues, increasing their metabolism. 
Vessels and Nerves.—The arteries supplying the thyroid gland are the 
superior and inferior thyroids and sometimes an additional branch 
(thyroidea ima) from the innominate artery or the arch of the aorta, 
which ascends upon the front of the trachea. The arteries are remarkable 
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for their large size and frequent anastomoses. The veins form a plexus 
on the surface of the gland and on the front of the trachea; from this 
plexus the superior, middle, and inferior thyroid veins arise; the superior 
and middle end in the internal jugular, the inferior in the innominate 
vein. The capillary blood vessels form a dense plexus in the connective 
tissue around the vesicles, between the epithelium of the vesicles and the 
endothelium of the lymphatics, which surround a greater or smaller part 
of the circumference of the vesicle. The lymphatic vessels run in the 
interlobular connective tissue, not uncommonly surrounding the arteries 
which they accompany, and communicate with a net-work in the capsule 
of the gland; they may contain colloid material. They end in the thoracic 
and right lymphatic trunks. The nerves are derived from the middle and 
inferior cervical ganglia of the sympathetic. 
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FUNCTION OF THE THYROID GLAND2 
Chemistry of Thyroid Hormones 
Thyroid hormones are derivatives of the the amino acid tyrosine 
bound covalently to iodine. The two principal thyroid hormones are:  
• thyroxine (also known as T4 or L-3,5,3',5'-tetraiodothyronine)  
• triiodotyronine (T3 or L-3,5,3'-triiodothyronine)  
As shown in the following diagram, the thyroid hormones are 
basically two tyrosines linked together with the critical addition of 
iodine at three or five positions on the aromatic rings. The number and 
position of the iodines is important. Several other iodinated molecules 
are generated that have little or no biological activity; so called "reverse 
T3" (3,3',5'-T3) is such an example.  
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 Large majority of the thyroid hormone secreted from the thyroid 
gland is T4, but T3 is the considerably more active hormone. Although 
some T3 is also secreted, the bulk of the T3 is derived by deiodination 
of T4 in peripheral tissues, especially liver and kidney. Deiodination of 
T4 also yields reverse T3, a molecule with no known metabolic activity.  
Thyroid hormones are poorly soluble in water, and more than 
99% of the T3 and T4 circulating in blood is bound to carrier proteins. 
The principle carrier of thyroid hormones is thyroxine-binding globulin, 
a glycoprotein synthesized in the liver. Two other carriers of import are 
transthyrein and albumin. Carrier proteins allow maintenance of a stable 
pool of thyroid hormones from which the active, free hormones are 
released for uptake by target cells.  
Synthesis and Secretion of Thyroid Hormones 
Thyroid hormones are synthesized by mechanisms fundamentally 
different from what is seen in other endocrine systems. Thyroid follicles 
serve as both factory and warehouse for production of thyroid 
hormones. 
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The entire synthetic process occurs in three major steps, which 
are, at least in some ways, analogous to those used in the manufacture of 
integrated circuits (ICs):  
• Production and accumulation of the raw materials (in the case of 
ICs, a large wafer of doped silicon)  
• Fabrication or synthesis of the hormones on a backbone or 
scaffold of precursor (etching several ICs on the silicon wafer)  
• Release of the free hormones from the scaffold and secretion into 
blood (cutting individual ICs out of the larger wafer and 
distributing them)  
The recipe for making thyroid hormones calls for two principle 
raw materials:  
• Tyrosines are provided from a large glycoprotein scaffold called 
thyroglobulin, which is synthesized by thyroid epithelial cells and 
secreted into the lumen of the follicle - colloid is essentially a 
pool of thyroglobulin. A molecule of thyroglobulin contains 134 
tyrosines, although only a handful of these are actually used to 
synthesize T4 and T3.  
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• Iodine, or more accurately iodide (I-), is avidly taken up from 
blood by thyroid epithelial cells, which have on their outer plasma 
membrane a sodium-iodide symporter or "iodine trap". Once 
inside the cell, iodide is transported into the lumen of the follicle 
along with thyroglobulin.  
Fabrication of thyroid hormones is conducted by the enzyme 
thyroid peroxidase, an integral membrane protein present in the apical 
(colloid-facing) plasma membrane of thyroid epithelial cells. Thyroid 
peroxidase catalyzes two sequential reactions:  
1. Iodination of tyrosines on thyroglobulin (also known as 
"organification of iodide").  
2. Synthesis of thyroxine or triiodothyronine from two iodotyrosines 
(also known as “coupling of iodotyrosines”) 
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Through the action of thyroid peroxidase, thyroid hormones 
accumulate in colloid, on the surface of thyroid epithelial cells. 
Remember that hormone is still tied up in molecules of thyroglobulin - 
the task remaining is to liberate it from the scaffold and secrete free 
hormone into blood.  
Thyroid hormones are excised from their thyroglobulin scaffold 
by digestion in lysosomes of thyroid epithelial cells. This final act in 
thyroid hormone synthesis proceeds in the following steps:  
• Thyroid epithelial cells ingest colloid by endocytosis from their 
apical borders - that colloid contains thyroglobulin decorated with 
thyroid hormone.  
• Colloid-laden endosomes fuse with lysosomes, which contain 
hydrolytic enzymes that digest thyroglobluin, thereby liberating 
free thyroid hormones.  
• Finally, free thyroid hormones apparently diffuse out of 
lysosomes, through the basal plasma membrane of the cell, and 
into blood where they quickly bind to carrier proteins for 
transport to target cells. 
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Control of Thyroid Hormone Synthesis and Secretion 
Each of the processes described above appears to be stimulated by 
thyroid-stimulating hormone from the anterior pituitary gland. Binding 
of TSH to its receptors on thyroid epithelial cells stimulates synthesis of 
the iodine transporter, thyroid peroxidase and thyroglobulin.  
The magnitude of the TSH signal also sets the rate of endocytosis 
of colloid - high concentrations of TSH lead to faster rates of 
endocytosis, and hence, thyroid hormone release into the circulation. 
Conversely, when TSH levels are low, rates of thyroid hormone 
synthesis and release diminish.  
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MECHANISM OF ACTION AND PHYSIOLOGIC EFFECTS OF 
THYROID HORMONES IN THE BODY 
Thyroid Hormone Receptors and Mechanism of Action 
Receptors for thyroid hormones are intracellular DNA-binding 
proteins that function as hormone-responsive transcription factors, very 
similar conceptually to the receptors for steroid hormones.  
Thyroid hormones enter cells through membrane transporter 
proteins. A number of plasma membrane transporters have been 
identified, some of which require ATP hydrolysis; the relative 
importance of different carrier systems is not yet clear and may differ 
among tissues. Once inside the nucleus, the hormone binds its receptor, 
and the hormone-receptor complex interacts with specific sequences of 
DNA in the promoters of responsive genes. The effect of the hormone-
receptor complex binding to DNA is to modulate gene expression, either 
by stimulating or inhibiting transcription of specific genes.  
For the purpose of illustration, consider one mechanism by which 
thyroid hormones increase the strength of contraction of the heart. 
Cardiac contractility depends, in part, on the relative ratio of different 
types of myosin proteins in cardiac muscle. Transcription of some 
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myosin genes is stimulated by thyroid hormones, while transcription of 
others in inhibited. The net effect is to alter the ratio toward increased 
contractility.  
Physiologic Effects of Thyroid Hormones 
It is likely that all cells in the body are targets for thyroid 
hormones. While not strictly necessary for life, thyroid hormones have 
profound effects on many "big time" physiologic processes, such as 
development, growth and metabolism. Many of the effects of thyroid 
hormone have been delineated by study of deficiency and excess states, 
as discussed briefly below.  
Metabolism: Thyroid hormones stimulate diverse metabolic activities 
of most tissues, leading to an increase in basal metabolic rate. One 
consequence of this activity is to increase body heat production, which 
seems to result, at least in part, from increased oxygen consumption and 
rates of ATP hydrolysis. By way of analogy, the action of thyroid 
hormones is akin to blowing on a smouldering fire. A few examples of 
specific metabolic effects of thyroid hormones include:  
• Lipid metabolism: Increased thyroid hormone levels stimulate fat 
mobilization, leading to increased concentrations of fatty acids in 
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plasma. They also enhance oxidation of fatty acids in many 
tissues. Finally, plasma concentrations of cholesterol and 
triglycerides are inversely correlated with thyroid hormone levels 
- one diagnostic indiction of hypothyroidism is increased blood 
cholesterol concentration.  
• Carbohydrate metabolism: Thyroid hormones stimulate almost all 
aspects of carbohydrate metabolism, including enhancement of 
insulin-dependent entry of glucose into cells and increased 
gluconeogenesis and glycogenolysis to generate free glucose.  
Growth: Thyroid hormones are clearly necessary for normal growth in 
children and young animals, as evidenced by the growth-retardation 
observed in thyroid deficiency. Not surprisingly, the growth-promoting 
effect of thyroid hormones is intimately intertwined with that of growth 
hormone, a clear indiction that complex physiologic processes like 
growth depend upon multiple endocrine controls.  
Development: A classical experiment in endocrinology was the 
demonstration that tadpoles deprived of thyroid hormone failed to 
undergo metamorphosis into frogs. Of critical importance in mammals is 
the fact that normal levels of thyroid hormone are essential to the 
development of the fetal and neonatal brain.  
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Other Effects: As mentioned above, there do not seem to be organs and 
tissues that are not affected by thyroid hormones. A few additional, 
well-documented effects of thyroid hormones include:  
• Cardiovascular system: Thyroid hormones increases heart rate, 
cardiac contractility and cardiac output. They also promote 
vasodilation, which leads to enhanced blood flow to many organs.  
• Central nervous system: Both decreased and increased 
concentrations of thyroid hormones lead to alterations in mental 
state. Too little thyroid hormone, and the individual tends to feel 
mentally sluggish, while too much induces anxiety and 
nervousness.  
• Reproductive system: Normal reproductive behavior and 
physiology is dependent on having essentially normal levels of 
thyroid hormone. Hypothyroidism in particular is commonly 
associated with infertility.  
Thyroid Disease States 
Disease is associated with both inadequate production and 
overproduction of thyroid hormones. Both types of disease are relatively 
common afflictions of man and animals.  
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Hypothyroidism is the result from any condition that results in 
thyroid hormone deficiency. Two well-known examples include:  
• Iodine deficiency: Iodide is absolutely necessary for production 
of thyroid hormones; without adequate iodine intake, thyroid 
hormones cannot be synthesized. Historically, this problem was 
seen particularly in areas with iodine-deficient soils, and frank 
iodine deficiency has been virtually eliminated by iodine 
supplementation of salt.  
• Primary thyroid disease: Inflammatory diseases of the thyroid 
that destroy parts of the gland are clearly an important cause of 
hypothyroidism.  
Common symptoms of hypothyroidism arising after early 
childhood include lethargy, fatigue, cold-intolerance, weakness, hair 
loss and reproductive failure. If these signs are severe, the clinical 
condition is called myxedema. In the case of iodide deficiency, the 
thyroid becomes inordinantly large and is called a goiter.  
The most severe and devastating form of hypothyroidism is seen 
in young children with congenital thyroid deficiency. If that condition is 
not corrected by supplemental therapy soon after birth, the child will 
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suffer from cretinism, a form of irreversible growth and mental 
retardation.  
Most cases of hypothyroidism are readily treated by oral 
administration of synthetic thyroid hormone. In times past, consumption 
of dessicated animal thyroid gland was used for the same purpose.  
Hyperthyroidism results from secretion of thyroid hormones. In 
most species, this condition is less common than hypothyroidism. In 
humans the most common form of hyperthyroidism is Graves disease, 
an immune disease in which autoantibodies bind to and activate the 
thyroid-stimulating hormone receptor, leading to continual stimulation 
of thyroid hormone synthesis. Another interesting, but rare cause of 
hyperthyroidism is so-called hamburger thyrotoxicosis.  
Common signs of hyperthyroidism are basically the opposite of 
those seen in hypothyroidism, and include nervousness, insomnia, high 
heart rate, eye disease and anxiety. Graves disease is commonly treated 
with anti-thyroid drugs (e.g. propylthiourea, methimazole), which 
suppress synthesis of thyroid hormones primarily by interfering with 
iodination of thyroglobulin by thyroid peroxidase. 
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The chief stimulator of thyroid hormone synthesis is thyroid-
stimulating hormone from the anterior pituitary. Binding of TSH to 
receptors on thyroid epithelial cells seems to enhance all of the 
processes necessary for synthesis of thyroid hormones, including 
synthesis of the iodide transporter, thyroid peroxidase and 
thyroglobulin.  
The magnitude of the TSH signal also sets the rate of endocytosis 
of colloid - high concentrations of TSH lead to faster rates of 
endocytosis, and hence, thyroid hormone release into the circulation. 
Conversely, when TSH levels are low, rates of thyroid hormone 
synthesis and release diminish.  
The thyroid gland is part of the hypothalamic-pituitary-thyroid 
axis, and control of thyroid hormone secretion is exerted by classical 
negative feedback, as depicted in the diagram. Thyroid-releasing 
hormone (TRH) from the hypothalamus stimulates TSH from the 
pituitary, which stimulates thyroid hormone release. As blood 
concentrations of thyroid hormones increase, they inhibit both TSH and 
TRH, leading to "shutdown" of thyroid epithelial cells. Later, when 
blood levels of thyroid hormone have decayed, the negative feedback 
signal fades, and the system wakes up again.  
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A number of other factors have been shown to influence thyroid 
hormone secretion. In rodents and young children, exposure to a cold 
environment triggers TRH secretion, leading to enhanced thyroid 
hormone release. This makes sense considering the known ability of 
thyroid hormones to spark body heat production. 
 
 
 
 
 
 
 
 
 
The hypothalamic-pituitary-thyroid axis 
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GOITER3 
A swollen thyroid is called a goiter. Most goiters are caused by 
not enough iodine in the diet. Iodine is a substance found in shellfish 
and iodized salt. 
Goiter is defined as an enlargement of the THYROID GLAND 
that may increase from about 20 grams to hundreds of grams in human 
adults. Goiter is observed in individuals with normal thyroid function 
(EUTHYROIDISM), thyroid deficiency (HYPOTHYROIDISM), or 
hormone overproduction (HYPERTHYROIDISM). Goiter may be 
congenital or acquired, sporadic or endemic (GOITER, ENDEMIC). 
Abnormally enlarged thyroid gland; can result from under-
production or over-production of hormone or from a deficiency of 
iodine in the diet 
A goitre (or goiter) (Latin struma), also called a bronchocele, is a 
swelling in the neck (just below adam's apple or larynx) due to an 
enlarged thyroid gland. They are classified in different ways: 
A "diffuse goitre" is a goitre that has spread through all of the 
thyroid (and is contrasted with a "simple goitre", "single thyroid nodule" 
and "multinodular goitre").  
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"Toxic goitre" refers to goitre with hyperthyroidism. These are 
derived from inflammation, neoplasm, and some kinds of activating 
autoimmune disease (Grave's disease). "Nontoxic goitre" (associated 
with normal or low thyroid levels) refers to all other types (such as that 
caused by lithium or certain other autoimmune diseases).  
Following is a list of underlying conditions that could possibly cause 
Goiter includes:  
Iodine deficiency  
Hypothyroidism  
Hyperthyroidism - goiters can arise from both increased and reduced 
thyroid hormones.  
Autoimmune thyroid disease  
Graves' disease  
Hashimoto's thyroiditis  
Other Thyroiditis  
Thyroid cyst  
Thyroid cancer  
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Puberty - can cause simple goiter  
Pregnancy - can cause simple goiter 
Inborn errors of metabolism causing defects in biosynthesis of thyroid 
hormones  
Exposure to radiation  
Deposition diseases  
Thyroid hormone resistance  
Goitrogenic foods - e.g. turnips 
Medications - e.g. lithium  
Some of the symptoms of Goiter include:  
Swollen front of the neck  
Physical symptoms due to goiter 
Protruding eyes  
Treatments for Goiter include: 
Iodine in diet - if goiter is caused by iodine deficiency  
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Thyroid replacement therapy  
Thyroxine  
Thyroidectomy - mainly for nodular goiter  
Antithyroid drugs – in Graves' disease 
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EUTHYROID GOITER4, 5 
Euthyroid goiter which is also known as Simple goiter, Nontoxic 
diffuse or nodular goiter occurs due to an enlargement of the thyroid 
gland but without clinical or laboratory evidence of thyroid 
dysfunction.4, 5 
Endemic goiter is defined as thyroid enlargement that occurs in 
more than 10% of a population, and sporadic goiter is a result of 
environmental or genetic factors that do not affect the general 
population. 
A simple goiter occurs when the thyroid gland is unable to meet 
the metabolic demands of the body through sufficient hormone 
production. The thyroid gland compensates by enlarging, which usually 
overcomes mild deficiencies of thyroid hormone. 
Pathophysiology 
The histopathology varies with etiology and age of the goiter. 
Initially, uniform follicular epithelial hyperplasia (diffuse goiter) is 
present with an increase in thyroid mass. As the disorder persists, the 
thyroid architecture loses uniformity, with the development of areas of 
involution and fibrosis interspersed with areas of focal hyperplasia. This 
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process results in multiple nodules (multinodular goiter). On nuclear 
scintigraphy, some nodules are hot, with high isotope uptake 
(autonomous) or cold, with low isotope uptake, compared with the 
normal thyroid tissue. The development of nodules correlates with the 
development of functional autonomy and reduction in thyroid-
stimulating hormone (TSH) levels. Clinically, the natural history of a 
nontoxic goiter is growth, nodule production, and functional autonomy 
resulting in thyrotoxicosis in a minority of patients. 
Race 
No convincing epidemiological studies suggest that race plays an 
important role in the development of nontoxic goiter. Generally, the 
lower socioeconomic conditions in nonindustrialized countries resulting 
in iodine deficiency have a more important role than race in the 
development of a goiter. 
Sex 
Diffuse and nodular goiter is more common in women than in 
men. According to the best estimate, 1.2-4.3 women have goiter for 
every man who has goiter. 
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Age 
Sporadic goiter from dyshormonogenesis, a genetic error in 
proteins that are necessary for thyroid hormone synthesis, occurs during 
childhood. Endemic goiter due to iodine deficiency occurs during 
childhood and continues to increase in size with age. Other causes of 
sporadic goiter rarely occur before puberty and do not have a peak age 
of occurrence. Thyroid nodules increase in incidence with age. 
Causes 
Most common worldwide cause of endemic nontoxic goiter is 
iodine deficiency. However, in patients with sporadic goiter, the cause is 
usually unknown. Nontoxic goiters have many etiologies, including the 
following: 
• Iodine deficiency: Goiter formation occurs with moderately 
deficient iodine intake of less than 50 mcg/d. Severe iodine 
deficiency associated with intake of less than 25 mcg/d is 
associated with hypothyroidism and cretinism.  
• Iodine excess: Goiter formation due to iodine excess is rare and 
usually occurs in the setting of preexisting autoimmune thyroid 
disease.  
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• Goitrogens  
o Drugs - Propylthiouracil, lithium, phenylbutazone, 
aminoglutethimide, iodine-containing expectorants  
o Environmental agents - Phenolic and phthalate ester 
derivatives and resorcinol found downstream of coal and 
shale mines  
o Foods - Vegetables of the genus Brassica (eg, cabbage, 
turnips, brussels sprouts, rutabagas), seaweed, millet, 
cassava, and goitrin in grass and weeds  
• Dyshormonogenesis: A defect in the thyroid hormone 
biosynthetic pathway is inherited.  
• Childhood head and neck radiation: Radiation exposure during 
childhood results in benign and malignant nodules. 
 30
WHO GRADING OF GOITERS 6, 7 
Grade 0: 
No goiter 
Grade Ia: 
Goiter detectable only by palpation and not visible when neck fully 
extended. 
Grade Ib: 
Goiter visible when neck fully extended and palpable. 
Grade II: 
Goiter visible when neck in natural position 
Grade III: 
Very large goiter visible from a considerable distance. 
Grade IV: 
Monstrous goiter. 
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WHO GRADING OF IODINE NUTRITION8 
Epidemiological criteria for assessing iodine nutrition based on median 
Urinary Iodine (UI) concentrations in school-age children 
Median 
UI(µg/l) 
Iodine intake Iodine nutrition 
<20  insufficient Severe iodine deficiency 
20-49 insufficient  Moderate iodine deficiency 
50-99 insufficient  Mild iodine deficiency 
100-199 Adequate  Optimal iodine nutrition  
200-299 
More than 
adequate 
Risk of iodine-induced hyperthyroidism 
within 5 - 10 years following introduction 
of iodized salt in susceptible groups 
=300 Excessive 
Risk of adverse health consequences 
(iodine induced hyperthyroidism, auto-
immune thyroid diseases) 
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REVIEW OF LITERATURE 
1. Suppressive therapy with levothyroxine for euthyroid diffuse and 
nodular goiter9 
Gullu S, Gurses MA, Baskal N, Uysal AR, Kamel AN, Erdogan G. 
Department of Endocrinology and Metabolic Diseases, Ankara 
University Medical School, Turkey. 
Endocr J. 1999 Feb;46(1):221-6. 
In this study, 35 patients with euthyroid diffuse goiter and 35 
patients with euthyroid nodular goiter were treated with Levothyroxine 
(L-T4) for six months. The mean decrease of thyroid volume at six 
months was about 20% (20.4 +/- 8.8 ml vs. 16 +/- 7.9 ml, P<0.001) in 
patients with diffuse goiter. A reduction of 50% or more in volume was 
detected in 31% (11/35) of the nodular goiter patients. 54% of the 
patients (19/35) showed a 10-49% decrease in nodule volume. Five of 
the patients were found to be insensitive to the therapy.  Free T4 and 
free T3 levels increased and TSH levels decreased with L-T4 treatment 
in all patient groups. Patients with higher TSH levels (within normal 
limits) showed more volume reduction in the diffuse goiter group. 
CONCLUSION: Suppressive thyroxine treatment is effective in 
reducing the size of the goiter, and nodules. 
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2. Efficacy of L-thyroxine (L-T4) therapy on the volume of the 
thyroid gland and nodules in patients with euthyroid nodular 
goiter10 
Diacinti D, Salabe GB, Olivieri A, D'Erasmo E, Tomei E, 
Lotz-Salabe H, De Martinis C. 
Istituto di Clinica Medica II, Universita di Roma, La Sapienza. 
Minerva Med. 1992 Nov;83(11):745-51. 
The efficacy of treatment with TSH suppressive doses of L-
thyroxine was evaluated by echography in 35 patients with euthyroid 
nodular goiter. Patients have been subdivided in two groups comparable 
for sex age and size of the goiter. Sixteen patients were treated for nine 
months with suppressive doses of thyroxine and nineteen were followed 
without therapy as control. Patients in treatment were then followed up 
for additional 9 months without therapy. The mean decrease of thyroid 
volume at nine months was 25% (27 +/- 10 ml vs 20 +/- 8 ml; p < 0.01). 
After discontinuation of treatment thyroid volume increased and had 
returned to base line values after nine months of follow up. In the 
control group mean thyroid volume had increased by 17.7% at nine 
months (28 +/- 17 vs 33 +/- 19 ml; p < 0.001). Thyroid nodules in 
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response to thyroid hormone treatment showed a variable behaviour: 
30.7% (4/13) of the nodules responded to the therapy with a reduction > 
to 25% at the ninth month; the remaining nodules were insensitive to the 
therapy.  
CONCLUSION: Suppressive thyroxine treatment is effective in 
reducing the goiter, nodules instead are only in part sensitive to the 
treatment. Thyroxine therapy of euthyroid nodular goiter must be 
followed for long term since upon thyroxine discontinuation there is a 
prompt reappearance of the goiter. 
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3. Ultrasound scanning assessment of L-thyroxine treatment 
effectiveness in a group of children with diffuse goiter11 
Regalbuto C, Belfiore A, Giuffrida D, Ippolito A, Motta RM, Sava L. 
Cattedra di Endocrinologia, University of Catania, Ospedale 
Garibaldi, Italy. 
J Endocrinol Invest. 1991 Sep;14(8):675-8 
In this prospectic study the effectiveness of one-year L-thyroxine 
treatment in a group of children with nontoxic diffuse goiter coming 
from an area with low iodine intake was evaluated by measuring the 
thyroid volume by ultrasound as ultrasound scanning is an accurate and 
objective method to assess thyroid volume and therefore useful to 
evaluate the effectiveness of L-thyroxine treatment in reducing goiter 
size, especially in children where clinical evaluation is inaccurate.  11 
children (7 females, 4 males), age range 9-14 years were examined. At 
clinical examination, 6 patients had a goiter classified Ia (according to 
WHO criteria), 4 had a class Ib and only 1 had a class II goiter. In order 
to achieve an accurate goiter evaluation, the thyroid volume was 
determined by ultrasonic scanning with a 5 MHz linear probe before 
and after treatment. Patients were given a dose of L-thyroxine (1.5-2.0 
micrograms/kg/day) in order to significantly reduce serum TSH levels 
 36
(from 1.8 +/- 0.6 to 0.8 +/- 0.5 mU/l, mean +/- SD). Patients were 
reexamined at 12 months of therapy and again at 10 months after 
therapy withdrawal. A significant reduction of the goiter volume 
(greater than 20%) was obtained in 6/11 (54%) patients, although 
serum TSH levels were fully suppressed only in one. The mean goiter 
size reduction in "responders" was -31.2 +/- 9.3% (m +/- SE). After 
therapy withdrawal goiter size increased in the majority of cases (in 
4/11, greater than 20%). 
CONCLUSION: L-thyroxine treatment is effective in reducing goiter 
size in the majority of children with a diffuse goiter. 
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4. Levothyroxine suppressive therapy in the medical 
management of nontoxic benign multinodular goiter12 
Celani MF 
Department of Medicine, Castelfranco Emilia Hospital, Modena, 
Italy. 
Exp Clin Endocrinol. 1993;101(5):326-32. 
The aim of this investigation was to evaluate the efficacy of 
levothyroxine suppressive therapy in the medical management of 
nontoxic benign multinodular goiter. 104 patients with multiple (2 to 5, 
mean = 2.5 +/- 0.7), solid (96%) or predominantly solid (4%), 
nonfunctional (68%) or hypofunctional (32%) thyroid nodules were 
studied. The benign (colloid) nature of 94% of the nodules was 
confirmed by fine-needle aspiration biopsy. All the patients received 
suppressive (2.2 micrograms per Kg body weight) daily oral doses of 
levothyroxine for 6 months. To confirm the effectiveness of the 
suppressive therapy, TSH levels were measured by an ultrasensitive 
immunometric assay at 3 and 6 month of treatment. For each patient, 
the volume of each nodule before and after levothyroxine therapy was 
evaluated by high-resolution ultrasonography. After 3 and 6 months of 
treatment, TSH levels were suppressed (lower than 0.1 mIU/l) in 75 
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patients and detectable in 29. At the end of the study, the volume of all 
the nodules was decreased by 50% or more (responder group) in 20/75 
(27%) of the patients with suppressed TSH levels, and in 3/29 (10%) of 
those with detectable TSH values. In the latter group the proportion of 
patients in which one or more nodule(s) showed an increase in volume 
(48%) was significantly higher (p < 0.0005) than in patients with 
suppressed TSH (29%).  
CONCLUSION: An effective TSH suppressive therapy is an useful 
tool in the treatment of nontoxic benign multinodular goiter. 
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5. The effect of treatment with levothyroxine or iodine on thyroid 
size and thyroid growth stimulating immunoglobulins in endemic 
goitre patients13 
Wilders-Truschnig MM, Warnkross H, Leb G, Langsteger W, Eber 
O, Tiran A, Dobnig H, Passath A, Lanzer G, Drexhage HA. 
Department of Medicine, Karl Franzens University, Graz, Austria. 
Clin Endocrinol (Oxf). 1993 Sep;39(3):281-6. 
The effect of levothyroxine or iodine on thyroid size and on 
thyroid growth stimulating immunoglobulins in endemic goitre patients 
was assessed in thirty seven euthyroid patients. Levothyroxine or iodine 
was given orally in an open randomized prospective study (100 and 200 
micrograms respectively). Thyroid size, thyroid growth stimulating 
immunoglobulins (mitosis arrest assay), basal TSH, free T3, free T4, 
thyroid anti-microsomal antibodies, antithyroglobulin antibodies, anti-
TSH receptor antibodies and urinary iodine excretion were measured. 
Thyroid size decreased significantly in both groups, in the levothyroxine 
group more than in the iodine treated group. Thyroid growth stimulating 
immunoglobulins levels also decreased significantly in both groups. 
Between groups there was no statistically significant difference. A 
statistically significant correlation between thyroid growth stimulating 
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immunoglobulins reduction profiles and goitre size reduction could not 
be established. TSH levels became suppressed in the levothyroxine 
group while the T4 values rose; in the iodine treated group TSH levels 
stayed constant as did T4. None of the patients developed thyroid 
microsomal or thyroglobulin auto-antibodies and/or hyperthyroidism 
during the treatment. 
CONCLUSION: Levothyroxine as well as iodine was effective in 
reducing thyroid size as well as thyroid growth stimulating 
immunoglobulins levels in endemic goitre patients. Since in both groups 
TSH levels were not related to thyroid size reduction, other factors than 
TSH suppression must be responsible for the observed thyroid size 
reduction. Iodine itself by virtue of its antiproliferative action on 
thyrocytes may have had a direct action on the goitre reduction during 
iodine treatment; however, the levothyroxine dose, containing less 
iodine, had a similar effect. 
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6. Treatment of juvenile goiter with levothyroxine, iodide or a 
combination of both: the value of ultrasound grey-scale analysis14 
Einenkel D, Bauch KH, Benker G. 
Department of Pediatrics, Hospital Erlabrunn, Germany. 
Acta Endocrinol (Copenh). 1992 Oct;127(4):301-6 
The effects of oral iodide, levothyroxine and of iodide and 
levothyroxine in combination were studied in three groups of 30 
children, age 13-15 years, with euthyroid goitre. As endpoints of this 
study, we used thyroid volume reduction, thyroid hormones, thyrotropin 
and thyroid grey-scale histograms by computerized analysis. The three 
groups were well matched with respect to mean age, body weight and 
pretreatment thyroid volumes and thyroid hormones. Mean urinary 
iodide excretion before treatment was in the range of 30 micrograms/g 
creatinine, since the study was conducted in an iodine-deficient area. All 
three treatment regimens led to significant reductions in thyroid volume 
within one month. After six months on 100 micrograms of 
levothyroxine, thyroid volume had decreased from 14.1 +/- 4.2 ml to 8.3 
+/- 2.6 ml (mean +/- SD); on 150 micrograms of iodide, from 18.5 +/- 
6.2 ml to 8.8 +/- 2.7 ml; and on 100 micrograms of iodide plus 50 
micrograms of levothyroxine, from 17.2 +/- 3.1 ml to 8.3 +/- 2.0 ml. 
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When treatment was discontinued for three months, or the dosage 
reduced, thyroid volume increased again in the levothyroxine (to 11.3 
+/- 2.5 ml) but not in the iodide group. Grey-scale values (by ultrasound, 
computer-aided estimation) after nine months were significantly 
different between the three treatment groups; no change was observed 
with levothyroxine, but after 150 micrograms of iodide as well as after 
combined treatment with levothyroxine and iodide there were marked 
decreases of grey-scale values; this is interpreted as reflecting a decrease 
in follicle size and colloid content of the thyroid which takes place after 
iodide supplementation. 
CONCLUSION: Iodide is the treatment of choice for iodine deficiency 
euthyroid goiters. 
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JUSTIFICATION OF THE STUDY 
• The efficacy of levothyroxine suppressive therapy in the 
treatment of euthyroid goiters is controversial 
• The literature contains conflicting reports, for and against 
levothyroxine,  regarding the treatment of euthyroid goiters  
For:  
• According to one school of thought mild thyroid failure and 
subtle sub clinical hypothyroidism may be present in Euthyroid 
goiters as evidenced by high TSH levels. Without treatment, mild 
thyroid failure may develop into overt hypothyroidism at a rate of 
5-26% per year. Hence treatment with thyroxine therapy is a 
must.15 
• It is also said that 60% or more of the Euthyroid goiters respond 
to suppressive doses of levothyroxine by significant reduction in 
goiter size as revealed by USG.15 
Against:  
• According to another school of thought levothyroxine has little 
role to play in the management of Euthyroid goiters as the single 
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most prevalent cause of these goiters is iodine deficiency. Hence 
iodide supplementation should be the mainstay of treatment. 
Prophylactic thyroxine is not superior to mere follow up care of 
euthyroid patients with autoimmune thyroiditis. Possible life long 
therapy and risk of thyrotoxicosis make thyroxine an unattractive 
option for treatment of nodular goiters. Thyroxine has no role for 
goitrogen induced thyromegaly and its role in dyshormonogenesis 
is under study.15 
• It is also said that the clinical observation of a “shrinking goiter” 
during thyroxine therapy is now well established by ultrasound 
investigations as a decrease in goiter volume of maximal 30 to 
40%, only within the first few months of treatment, but after that 
no further significant reduction in goiter size has been 
demonstrated so far and abrupt withdrawal of thyroxine therapy 
results in a rebound increase of goiter volume within a few 
weeks.15 
• To resolve these issues a well conducted study focusing on the 
above aspects becomes necessary. Hence the present study was 
undertaken. 
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AIMS AND OBJECTIVES OF THE STUDY 
1. To study the complete clinical and biochemical profile of the 
children with Euthyroid goiters. 
2. To evaluate the effect of thyrotropin (TSH) suppressive 
therapy with levothyroxine on the size of diffuse, multinodular 
and solitary nodular Euthyroid goiters in the pediatric population. 
3. To study the side-effect profile of levothroxine therapy, if any.  
4. To ascertain the existence of iodine deficiency in our pediatric 
population as it is the most important cause of Euthyroid goiters. 
5. To study different pathologies of euthyroid goiters as evidenced 
by FNAC. 
6. To evaluate the incidence of euthyroid goiters at the pediatric 
endocrinology department of Institute of Child Health and 
Hospital for Children 
7. To compare this study with other similar kinds of studies. 
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SUBJECTS AND METHODS 
METHODOLOGY 
Study Design: Prospective randomized controlled trial comparing 
pediatric cases with Euthyroid goiter treated with levothyroxine as 
Study Group and a matched group with untreated Euthyroid goiter as 
Control Group. 
Place of study: Endocrinology department of Institute of Child Health 
and Hospital for Children. 
Period of study: October 2005 to September 2006. 
Subjects: Pediatric patients with Euthyroid goiter attending the 
endocrine OPD of Institute of Child Health and Hospital for Children. 
Sample size: For a confidence level of 95% with a confidence interval of 
+/- 5%, 37 cases and 37 controls were taken into the study. 
Sampling technique: Random sampling. 
Inclusion criteria: All children with Euthyroid goiters. 
Exclusion criteria: Children with goiters due to hypothyroidism or 
hyperthyroidism. 
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MANOEUVRE 
Patients were selected by random sampling based on the above set of 
criteria 
Patients were subdivided into two groups (study and control) 
comparable for sex, age and size of the goiter. 
Patients in the age group of 6 to 12, having grade 2 and above goiters 
with T3, T4 and TSH, measured by standard Radioimmunoassay 
(RIA) technique, in the normal range i.e. having Euthyroid goiters were 
admitted to the study. 
The volume of the thyroid gland was measured at commencement of 
study by USG using 7.5MHZ high frequency probe.16, 17 
The pathology of the euthyroid goiter was determined by FNAC. 
Urinary iodine is a good biochemical marker for control of iodine 
deficiency disorders.18Most of the popular methods for urinary iodine 
determination are based on the Sandell–Kolthoff reaction.19The chloric 
acid digestion is the most commonly used but is hazardous.20Hence a 
simple, rapid, and quantitative method based on the Sandell–Kolthoff 
reaction, which uses the safer ammonium persulfate digestion, 
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incorporating both the reaction and the digestion process into a 
microplate format was adopted.21 
Spot Urinary iodine levels were measured to determine the iodine status 
by Simple Microplate Method22 for determination of Urinary Iodine, 
utilizing the principle of Wet ashing.18 
Using a specially designed sealing cassette to prevent loss of vapor and 
cross-contamination among wells, ammonium persulfate digestion was 
performed in a microplate in an oven at 110 °C for 60 min. After the 
digestion mixture was transferred to a transparent microplate and the 
Sandell–Kolthoff reaction was performed at 25 °C for 30 min, urinary 
iodine was measured by a microplate reader at 405 nm. 
Experimental procedure 
APDM method22 
1. Calibrators and urine samples (50 µL each) were pipetted into the 
wells of a polypropylene (PP) plate, followed by the addition of 
100 µL of ammonium persulfate solution (final concentration, 
0.87 mol/L).  
2. The PP plate was set in a cassette.  
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3. The cassette was tightly closed and was kept for 60 min in an 
oven adjusted to 110 °C.  
4. After digestion, the bottom of the cassette was cooled to room 
temperature with tap water to avoid condensation of vapor on the 
top of wells and to stop the digestion.  
5. The cassette was opened, and 50-µL aliquots of the resulting 
digests were transferred to the corresponding wells of a 
polystyrene 96-well microtiter plate (MicroWell; Nalge Nunc 
International).  
6. Arsenious acid solution (100 µL) was added to the wells and 
mixed. 
7. 50 µL of ceric ammonium sulfate solution was then added 
quickly (within 1 min), using a multichannel pipette (Finnpipette 
Varichannel; Labsystems).  
8. The reaction mixture was allowed to sit for 30 min at 25 °C, and 
the absorbance was measured at 405 nm with a microplate reader. 
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Sealing cassette used for digestion after a microplate is placed inside 
 The children in the study group were administered levothyroxine at a 
suppressive dose of 2µ/kg/day.11, 12 
At the end of six months, thyroid function tests and ultrasound 
examinations were repeated in both the study and control groups. 
STATISTICAL ANALYSIS 
Standard statistical methods were applied to arrive at the p value, 
correlation coefficient and other statistical parameters with the help of 
statistician on computer and the results tabulated. 
OBSERVATIONS 
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OBSERVATIONS 
The p value of the various variables studied in the study 
Study group 
Parameter 
mean 
At 
commencement 
After 6 months P value 
Thyroid volume 
(CC) 
5.26 3.86 0.000 
T3 (ng/dl) 138.73 150.39 0.013 
T4 (µg/dl) 7.83 11.1 0.000 
TSH (µIU/ml) 2.57 0.76 0.000 
 
Control group 
Parameter 
mean 
At 
commencement 
After 6 months P value 
Thyroid volume 
(CC) 
5.84 5.78 0.521 
T3 (ng/dl) 149.57 141.26 0.000 
T4 (µg/dl) 8.06 7.02 0.000 
TSH (µIU/ml) 3.24 4.52 0.000 
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Iodine status 
Study group Control group Iodine 
deficiency 
N % N % 
P value 
None 3 8.1 3 8.1 1.000 
Mild 25 67.6 32 86.5 0.3538 
Moderate 8 21.6 2 5.4 0.0578 
Severe 1 2.7 0 0 0.998 
 
Histology 
Study group Control group Type 
N % N % 
P value 
Colloid Goiter 30 81.1 35 94.6 0.5351 
Hashimoto’s 
Thyroiditis 
6 16.2 2 5.4 0.1573 
Sub acute 
Granulomatous 
Thyroiditis 
1 2.7 0 0 0.998 
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Gender distribution 
Study group Control group Gender 
N % N % 
P value 
Girls 28 75.7 32 86.5 0.6056 
Boys 9 24.3 5 13.5 0.2850 
 
Age distribution 
Ages Study group Control group P value 
6-12 34 34 1.000 
 
The above tables show that in the study group, all parameters showed 
significant change (p <0.05) due to levothyroxine therapy where as in 
the control group, thyroid volume did not show any significant 
change (p >0.05). Other tables show that the variations of variables in 
the study and control groups are not significant (p >0.05) and hence 
they are matched for all practical purposes. 
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Change in the mean volume of thyroid at Commencement and after 
6 months in Study and Control groups 
Study Group 
Volume of Thyroid (CC) Mean SD 
At Commencement 5.26 2.61 
After 6 months 3.86 1.61 
 
Decrement in the mean volume of thyroid is 27% 
P value is 0.000 (< 0.01, statistically significant at **) 
Control Group 
Volume of Thyroid (CC) Mean SD 
At Commencement 5.84 2.00 
After 6 months 5.78 2.13 
 
Decrement in the mean volume of thyroid is 1% 
P value is 0.521 (> 0.05, statistically not significant) 
Inference: All patients show response to levothyroxine therapy. 
Levothyroxine at suppressive dose causes decrement in the thyroid 
volume at the end of six months which is statistically significant. 
 55
Percentage of children showing none (>100mcg/L), mild (50-
99mcg/L), moderate (20-49mcg/L) or severe (<20mcg/L) Iodine 
deficiency 
 None Mild Moderate Severe 
Study Group 3 25 8 1 
Control 
Group 
3 32 2  
Total 6 57 10 1 
Percentage 8.1 77 13.5 1.4 
 
Inference: 77%, 13.5% and 1.4% of the total children studied have 
mild, moderate and severe iodine deficiency respectively. On the 
whole 91.9% of the total euthyroid goiter patients in this study have 
some kind of iodine deficiency. 
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Percentage of children in the study group showing factitious (sub 
clinical) hyperthyroidism i.e. elevation of T3 and/or T4 or 
suppression of TSH due to levothyroxine suppressive therapy 
T3 
(ng/dl) 
Number of 
children 
having normal 
T3 
Number of 
children having 
abnormal T3 
(elevated) 
Percentage 
of children 
having 
abnormal T3
At Commencement 37 0 0 
After 6 months 35 2 5.4 
 
T4 
(µg/dl) 
Number of 
children 
having normal 
T4 
Number of 
children having 
abnormal T4 
(elevated) 
Percentage 
of children 
having 
abnormal T4
At Commencement 37 0 0 
After 6 months 18 19 51.4 
 
TSH 
(µIU/ml) 
Number of 
children 
having normal 
TSH 
Number of 
children having 
abnormal TSH 
(suppressed) 
Percentage 
of children 
having 
abnormal 
TSH 
At 
Commencement 
37 0 0 
After 6 months 14 23 62.2 
 
Inference: Percentage of children showing factitious (sub clinical) 
hyper thyroidism i.e. elevation of T3 and/or T4 or suppression of TSH is 
62.2%. Among the 6 patients with Hashimoto’s in the levothyroxine 
group 3 showed suppression of TSH < 0. 3 with levothyroxine therapy 
and 3 did not.  
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Histology wise distribution of Euthyroid goiters based on FNAC  
Colloid Goiter Hashimoto’s 
Thyroiditis 
Sub acute 
Granulomatous 
Thyroiditis 
 
N % N % N % 
Study Group 30 81.1 6 16.2 1 2.7 
Control Group 35 94.6 2 5.4   
Total 65 87.8 8 10.8 1 1.4 
 
Inference: Most of the Euthyroid goiters are simple colloid goiters 
(87.8%). 
Mean decrement in volume of thyroid due to levothyroxine in 
different types of goiters in the Study group 
Type of goiter Mean volume of 
thyroid at 
commencement 
Mean volume 
of thyroid 
after 6 
months 
Percentage 
decrement 
Colloid Goiter 4.98 3.90 22 
Hashimoto 
Thyroiditis 
7.17 3.97 45 
Sub acute 
Granulomatous 
Throiditis 
2.20 2 10 
 
Inference: Hashimoto’s thyroiditis shows the maximum response to 
levothyroxine suppressive therapy with a mean decrement of 45%. 
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Gender distribution of Euthyroid goiter patients 
Variable Study group Control group Total 
Girls 28 32 60 
Percentage of 
girls 
75.7 86.5 81.1 
Boys 9 5 14 
Percentage of 
boys 
24.3 13.5 18.9 
 
Inference: 81.1% of the Euthyroid goiter patients studied were girls 
and and 18.9% were boys. 
In our study 70 were diffuse goiters and 4 were multi nodular goiters, 
2 each in study and control groups. The overall behavior of nodular 
goiters with or without levothyroxine therapy was similar to that of the 
colloid goiters. 
All the goiters studied were grade II goiters. 
None of the patients had any actual side-effects. 
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MEAN THYROID VOLUME IN THE STUDY AND CONTROL 
GROUP AT COMMENCEMENT AND AFTER SIX MONTHS 
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IODINE DEFICIENCY OBSERVED IN 
CHILDREN WITH EUTHYROID GOITERS
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GENDER DISTRIBUTION OF EUTHYROID GOITER 
PATIENTS FOR DIFFERENT AGES 
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SOME OF OUR EUTHYROID GOITER PATIENTS 
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DISCUSSION 
The present study depicts that the incidence of grade II euthyroid 
goiters is 1.5% in the pediatric population aged 6 to 12 in the 
endocrinology department of Institute of Child Health and Hospital for 
Children. This could only be tip of the ice berg as this is hospital based 
and not community based study. The occurrence of euthyroid goiter 
depends on the endemicity of the area. The incidence is more in the 
endemic zones when compared to non endemic areas. This could be 
because of the difference in the iodine content of the soil in different 
places. Generally higher altitude areas which are above the sea level are 
endemic zones of euthyroid goiters as the iodine content of the soil and 
hence that of the vegetables and fruits grown in that soil is generally 
deficient. Also sea food is a rich source of iodine which is not available 
at high altitudes.4, 5 
In the present study we found that the most common cause of 
euthyroid goiter in pediatric population aged 6 to 12 is probably iodine 
deficiency as 91.9% of the children studied had iodine deficiency with 
mild iodine deficiency being most common at 77%. World over the 
most common cause of euthyroid endemic goiters is iodine deficiency. 
This is again substantiated in our study. This shows that even in a non 
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endemic zone like ours at least mild iodine deficiency does exist in 
children with euthyroid goiters. This could be because of the cultural 
practices. Traditionally and culturally in many families rock salt is still 
being widely used instead of iodized salt. Due to this iodine deficiency 
disorders like euthyroid goiter exist even in non endemic zones like the 
one where the present study was conducted.4, 5 
The mean percentage decrease in the size of the goiter after six 
months of levothyroxine therapy in the study group is 27% in our study. 
Others have found out similar kind of decrement.  Thyroid gland volume 
was static in the control group. In the study by Gullu S, et al9 on 35 
patients with euthyroid diffuse goiter and 35 patients with euthyroid 
nodular goiter, the mean decrease of thyroid volume at six months was 
about 20% for diffuse euthyroid goiters. Nodular goiters showed 
variable response with a reduction in size by 50% or more or nil 
decrement in size. Diacinti D, et al10 in their study on 35 patients with 
euthyroid nodular goiters observed 25% mean decrease of thyroid 
volume after nine months of levothyroxine therapy in the study group. 
Nodules instead were found to be only in part sensitive to the treatment. 
Thyroid volume was static with no decrement or rather increased in the 
control group. They found goiter reappeared on discontinuation of 
levothyroxine therapy. Regalbuto C, et al11 in their study on diffuse 
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goiters in children observed significant decline of more than 20% in 
children with euthyroid goiter on levothyroxine suppressive therapy for 
12 months. They found the goiter size to increase on discontinuation of 
therapy. Celani MF12 in his study with multinodular goiters found 
nodules behaving variably with a decrease by 50% or more or nil on 
levothyroxine suppressive therapy. Wilders-Truschnig MM, et al13 in 
their study on 37 euthyroid patients concluded that levothyroxine as well 
as iodine was effective in reducing the thyroid size. Einenkel D, et al14 
in there study on treatment of juvenile goiter with three groups of 30 
each with levothyroxine, iodide or a combination of both found a 
decrement of 41%, 52% and 52% respectively. When the treatment was 
discontinued for three months, thyroid volume increased again in the 
levothyroxine group but not in the iodide group.  
From the above discussion it is evident that levothyroxine therapy 
in suppressive doses does result in a significant decrement in the size of 
euthyroid goiters. In our study also we found a statistically significant 
decline in thyroid volume in levothyroxine group in 6 months at a 
suppressive dose of 2mcg/kg/day.11,12 Other studies have shown that this 
reduction in goiter size does not sustain if levothyroxine therapy is 
withdrawn. This aspect needs to be further elucidated.  
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Again a few of the above mentioned studies have shown that with 
iodine treatment for euthyroid goiters the reduction in goiter size was 
significant and moreover was sustained even after its withdrawal. In our 
study also we found at least mild iodine deficiency to be rampant in 
children with euthyroid goiters. Perhaps this is a pointer that euthyroid 
goiters can be better managed with iodine supplementation in the face of 
iodine deficiency. This aspect of our study needs to be further 
elucidated.  
Most of the children in the study group showed a rise in T3, T4 
and a significant decline of TSH level after six months. More the decline 
more was the volume reduction. 62.2% of children in the study group 
developed sub clinical hyperthyroidism in the study group on 
levothyroxine with TSH falling < 0.3µIU/ml. Other studies have also 
documented the suppression of TSH. Gullu S, et al found TSH levels 
decreased with levothyroxine therapy in all patient groups.9 Regalbuto 
C, et al also found TSH levels to significantly reduce and was fully 
suppressed in one patient.11 Celani MF found TSH to fall below 
0.1µIU/ml in 75 patients, which is 72%, of the total 104 patients 
studied.12 Wilders-Truschnig MM, et al found that TSH levels became 
suppressed while T4 values rose in the levothyroxine treated group; in 
the iodine treated group TSH levels remained constant as did T4.13  
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None of the authors have reported any side effects due to 
levothyroxine treatment in a suppressive dosage.9, 10, 11, 12, 13, 14 This holds 
good for our study too where none of the patients had any actual side 
effects due to suppressive levothyroxine therapy. 
87.8% of children in our study had simple colloid Euthyroid 
goiters as shown by FNAC which confirms the most common pathology 
of these goiters as established world over. Celani MF also in his study 
on euthyroid goiters found 94% of the 104 goiter patients studied to be 
having benign colloid goiter by FNAC.12 
The greatest decrement of thyroid volume after levothyroxine 
therapy was found to be in Euthyroid goiter patients with Hashimoto’s 
thyroiditis at 45%. Among the 6 patients with Hashimoto’s in the 
levothyroxine group 3 showed suppression of TSH with levothyroxine 
therapy and 3 did not. Hence follow up care of euthyroid patients with 
autoimmune thyroiditis needs to be considered initially. 
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SUMMARY 
• Iodine deficiency is the most common cause of Euthyroid goiters. 
• Levothyroxine at a suppressive dose of 2µ/kg/day for 6 months 
causes a significant decline in the size of the thyroid gland as 
measured by USG. 
• Children on levothyroxine suppressive therapy are likely to 
develop sub clinical hyperthyroidism which may be reversible 
after discontinuation of the therapy. 
• Most of the Euthyroid goiters are colloid goiters as proved by 
FNAC. 
• Greatest decrement in size observed in Euthyroid goiter patients 
due to Hashimoto’s thyroiditis after levothyroxine suppressive 
therapy, shows that this type of goiter responds best to 
levothyroxine therapy. 
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CONCLUSION 
• The cosmetic misery of Euthyroid goiters in children was focused 
in the present study. 
• Deficiency of iodine necessary for hormonogenesis and 
prevention of goiters is the most common cause resulting in 
Euthyroid goiters which is well substantiated in our study. 
• Suppressive levothyroxine therapy for a destined period of 6 
months resulted in appreciable decline in the size of the goiter 
both clinically and when viewed through sonologically, thus 
comforting the patients. 
• This study thus proves the usefulness of levothyroxine therapy in 
these subjects. The usage of iodine will further prove to be helpful 
in reducing the goiter size, more so with Hashimoto’s thyroiditis 
along with levothyroxine therapy. 
• Reversible iatrogenic sub clinical hyperthyroidism is observed in 
quite a number of patients in this study. 
• This study is the first institution based amongst South Indian 
children which unravels the usefulness of measuring urinary 
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iodine in all Euthyroid goiters which will give an insight into 
management protocol and highlights the usefulness of 
levothyroxine suppressive therapy. 
• Though the study is done in fewer sample size, future studies in 
larger numbers will be more useful and meaningful to substantiate 
our findings.  
ANNEXURE 1 – PROFORMA 
 
 
PROFORMA 
 
Name: 
Name:  
Date of inclusion:Age:Sex: 
Postal address:Telephone number:Father’s name: 
Mother’s name: 
Endocrine OPD number: 
Anthropometrics: 
Clinical examination: 
Clinical grade of the goiter: 
    
Thyroid function tests: 
1. T3 
2. T4 
3. TSH            
FNAC of the goiter: 
Size of the goiter by USG: 
Urinary iodine level: 
Follow up: 
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